Home » Targacept Backpedals on TC-6987 After Data Analysis Error
Targacept Backpedals on TC-6987 After Data Analysis Error
Targacept’s asthma candidate TC-6987 met only one of its co-primary
endpoints in a Phase II study, the company revealed Tuesday, placing the
asthma indication on shakier ground than previously reported. The
company initially said TC-6987 met both its co-endpoints of change in
forced expiratory volume (FEV1) compared with placebo when measured from
baseline to pre-dosing on day 28 and when measured from baseline to two
hours post-dosing on day 28.
Drug Industry Daily
Drug Industry Daily
Upcoming Events
-
07May
-
14May
-
30May